|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61P 35/00 | |
| A61K 39/395 | |||
| A61K 39/00 | |||
| A61K 31/33 | |||
| A61K 35/15 | |||
| A61K 45/06 | |||
| A61P 7/00 | |||
| A61K 31/4745 | |||
| A61K 31/713 | |||
| A61K 31/519 | |||
| C12N 5/0786 |
| (11) | Patento numeris | 3247464 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16740762.6 |
| Europos patento paraiškos padavimo data | 2016-01-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-11-29 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-09-18 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/014334 |
| Data | 2016-01-21 |
| (87) | Numeris | WO 2016/118754 |
| Data | 2016-07-28 |
| (30) | Numeris | Data | Šalis |
| 201562106050 P | 2015-01-21 | US |
| (72) |
WEISSMAN, Irving L., US
FENG, Mingye, US
VOLKMER, Jens-Peter, US
|
| (73) |
The Board of Trustees of the Leland Stanford Junior University,
Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038,
US
|
| (54) | USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS |
| USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS |